Memorial Sloan Kettering Cancer Center: Carcinoma, Transitional Cell trials

The registry lists 17 Carcinoma, Transitional Cell studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 3 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 12No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingNCT07532902Phase 1
• A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial CarcinomaRecruitingNCT07390617
• A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin CancerRecruitingNCT05562791Phase 1
• Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based ChemotherapyTerminatedNCT01622660Phase 2Results posted
• Buparlisib in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT01551030Phase 2Results posted
• Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial CarcinomaCompletedNCT01261728Phase 2Results posted
• Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00805129Phase 2Results posted
• Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT00714948Phase 2Results posted
• Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial CarcinomaCompletedNCT00588666Phase 2Results posted
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT00397488Phase 2Results posted
• A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary TractActive, not recruitingNCT05868265Phase 2
• Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2
• A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerCompletedNCT03093922Phase 2
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2
• Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and StagingCompletedNCT00612326
• Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney CancerCompletedNCT00003342Phase 1
• Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder CancerCompletedNCT00003105Phase 1/2